Navigation Links
BioMarin to Present at the Oppenheimer Healthcare Conference
Date:10/27/2009

NOVATO, Calif., Oct. 27 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Hank Fuchs, M.D., Chief Medical Officer of BioMarin, will present a company update at the Oppenheimer Healthcare Conference in New York City on Tuesday, November 3, 2009 at 1:35 p.m. ET.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is in Phase II clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

    Contacts:

    Investors                             Media
    Eugenia Shen                          Susan Berg
    BioMarin Pharmaceutical Inc.          BioMarin Pharmaceutical Inc.
    (415) 506-6570                        (415) 506-6594

SOURCE BioMarin Pharmaceutical Inc.


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Acquires Huxley Pharmaceuticals, Inc.
2. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
3. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
6. BioMarin Announces FDA Approval for Kuvan
7. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
8. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
9. Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego
10. STAAR Surgical to Present at the 20th Annual Oppenheimer Healthcare Conference in New York
11. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... DUBLIN , May 4, 2016 /PRNewswire/ ... the addition of the  "Global Acute Myeloid ... 2016"  report to their offering.  ... ,Global Acute Myeloid Leukemia Market and Competitive ... Acute Myeloid Leukemia pipeline products, Acute Myeloid ...
(Date:5/3/2016)... May 4, 2016 Global ... pages, profiling 09 key companies and supported with ... and in-depth study on the current state of ... of the industry including definitions, classifications, applications and ... is provided for the international market including development ...
(Date:5/3/2016)... -- Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling ... ... ... ... ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... 05, 2016 , ... Linfield College Online and Continuing Education is encouraging registered ... $50 application fee for all qualified applicants from May 1–14. Students need only go ... when applying . , With the RN to BSN degree program, ...
(Date:5/5/2016)... ... 05, 2016 , ... In an effort to increase public ... health promotion and research organization, declared May as “National Sunshine Month.” , ... in cultural behavior over the past several decades, Americans spend more time indoors ...
(Date:5/4/2016)... ... May 05, 2016 , ... The talus is the part ankle that ... or traffic accidents can cause the talus bone to be fractured, and a high ... a first-of-its-kind procedure using 3D printing technology, internationally renowned orthopedic surgeon Dr. Mark ...
(Date:5/4/2016)... ... May 04, 2016 , ... The ... of its innovative kicking trainers to St. Jude Children’s Research Hospital to benefit ... durable, lightweight rubber band designed to teach children how to kick a soccer ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... families of Camas and Vancouver, WA, has announced the latest beneficiary of ... Breast Cancer Foundation and their Mammography Program, which provides free mammograms and ...
Breaking Medicine News(10 mins):